Exide Industries Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 10, 2025, 8:55 pm

Competitors of Exide Industries Ltd

All Competitor Stocks of Exide Industries Ltd

Quarterly Result

Last Updated: August 20, 2025, 11:00 am

Below is a detailed analysis of the quarterly data for Exide Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 4,695.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,335.00 Cr. (Mar 2025) to 4,695.00 Cr., marking an increase of 360.00 Cr..
• For Expenses, as of Jun 2025, the value is 4,157.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,907.00 Cr. (Mar 2025) to 4,157.00 Cr., marking an increase of 250.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 538.00 Cr.. The value appears strong and on an upward trend. It has increased from 428.00 Cr. (Mar 2025) to 538.00 Cr., marking an increase of 110.00 Cr..
• For OPM %, as of Jun 2025, the value is 11.00%. The value appears strong and on an upward trend. It has increased from 10.00% (Mar 2025) to 11.00%, marking an increase of 1.00%.
• For Other Income, as of Jun 2025, the value is 28.00 Cr.. The value appears to be declining and may need further review. It has decreased from 44.00 Cr. (Mar 2025) to 28.00 Cr., marking a decrease of 16.00 Cr..
• For Interest, as of Jun 2025, the value is 32.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 35.00 Cr. (Mar 2025) to 32.00 Cr., marking a decrease of 3.00 Cr..
• For Depreciation, as of Jun 2025, the value is 149.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 148.00 Cr. (Mar 2025) to 149.00 Cr., marking an increase of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 385.00 Cr.. The value appears strong and on an upward trend. It has increased from 290.00 Cr. (Mar 2025) to 385.00 Cr., marking an increase of 95.00 Cr..
• For Tax %, as of Jun 2025, the value is 29.00%. The value appears to be improving (decreasing) as expected. It has decreased from 35.00% (Mar 2025) to 29.00%, marking a decrease of 6.00%.
• For Net Profit, as of Jun 2025, the value is 275.00 Cr.. The value appears strong and on an upward trend. It has increased from 188.00 Cr. (Mar 2025) to 275.00 Cr., marking an increase of 87.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 3.21. The value appears strong and on an upward trend. It has increased from 2.20 (Mar 2025) to 3.21, marking an increase of 1.01.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 3:52 pm

Growth

Last Updated: September 5, 2025, 3:50 am

Balance Sheet

Last Updated: October 10, 2025, 1:59 pm

Below is a detailed analysis of the balance sheet data for Exide Industries Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 85.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 85.00 Cr..
• For Reserves, as of Mar 2025, the value is 13,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 12,801.00 Cr. (Mar 2024) to 13,828.00 Cr., marking an increase of 1,027.00 Cr..
• For Borrowings, as of Mar 2025, the value is 2,017.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 1,123.00 Cr. (Mar 2024) to 2,017.00 Cr., marking an increase of 894.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 5,459.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4,140.00 Cr. (Mar 2024) to 5,459.00 Cr., marking an increase of 1,319.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 21,390.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 18,149.00 Cr. (Mar 2024) to 21,390.00 Cr., marking an increase of 3,241.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 3,935.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,853.00 Cr. (Mar 2024) to 3,935.00 Cr., marking an increase of 82.00 Cr..
• For CWIP, as of Mar 2025, the value is 3,643.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,352.00 Cr. (Mar 2024) to 3,643.00 Cr., marking an increase of 2,291.00 Cr..
• For Investments, as of Mar 2025, the value is 6,468.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,940.00 Cr. (Mar 2024) to 6,468.00 Cr., marking an increase of 528.00 Cr..
• For Other Assets, as of Mar 2025, the value is 7,343.00 Cr.. The value appears strong and on an upward trend. It has increased from 7,004.00 Cr. (Mar 2024) to 7,343.00 Cr., marking an increase of 339.00 Cr..
• For Total Assets, as of Mar 2025, the value is 21,390.00 Cr.. The value appears strong and on an upward trend. It has increased from 18,149.00 Cr. (Mar 2024) to 21,390.00 Cr., marking an increase of 3,241.00 Cr..

Notably, the Reserves (13,828.00 Cr.) exceed the Borrowings (2,017.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Exide Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 9.35. This value is within the healthy range. It has decreased from 10.31 (Mar 24) to 9.35, marking a decrease of 0.96.
• For Diluted EPS (Rs.), as of Mar 25, the value is 9.35. This value is within the healthy range. It has decreased from 10.31 (Mar 24) to 9.35, marking a decrease of 0.96.
• For Cash EPS (Rs.), as of Mar 25, the value is 16.26. This value is within the healthy range. It has decreased from 16.97 (Mar 24) to 16.26, marking a decrease of 0.71.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 163.69. It has increased from 151.78 (Mar 24) to 163.69, marking an increase of 11.91.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 163.69. It has increased from 151.78 (Mar 24) to 163.69, marking an increase of 11.91.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 202.80. It has increased from 197.29 (Mar 24) to 202.80, marking an increase of 5.51.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 22.48. This value is within the healthy range. It has increased from 22.44 (Mar 24) to 22.48, marking an increase of 0.04.
• For PBIT / Share (Rs.), as of Mar 25, the value is 15.63. This value is within the healthy range. It has decreased from 15.84 (Mar 24) to 15.63, marking a decrease of 0.21.
• For PBT / Share (Rs.), as of Mar 25, the value is 13.83. This value is within the healthy range. It has decreased from 14.48 (Mar 24) to 13.83, marking a decrease of 0.65.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 9.41. This value is within the healthy range. It has decreased from 10.38 (Mar 24) to 9.41, marking a decrease of 0.97.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.35. This value is within the healthy range. It has decreased from 10.31 (Mar 24) to 9.35, marking a decrease of 0.96.
• For PBDIT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has decreased from 11.37 (Mar 24) to 11.08, marking a decrease of 0.29.
• For PBIT Margin (%), as of Mar 25, the value is 7.70. This value is below the healthy minimum of 10. It has decreased from 8.03 (Mar 24) to 7.70, marking a decrease of 0.33.
• For PBT Margin (%), as of Mar 25, the value is 6.81. This value is below the healthy minimum of 10. It has decreased from 7.33 (Mar 24) to 6.81, marking a decrease of 0.52.
• For Net Profit Margin (%), as of Mar 25, the value is 4.64. This value is below the healthy minimum of 5. It has decreased from 5.26 (Mar 24) to 4.64, marking a decrease of 0.62.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 4.61. This value is below the healthy minimum of 8. It has decreased from 5.22 (Mar 24) to 4.61, marking a decrease of 0.61.
• For Return on Networth / Equity (%), as of Mar 25, the value is 5.71. This value is below the healthy minimum of 15. It has decreased from 6.80 (Mar 24) to 5.71, marking a decrease of 1.09.
• For Return on Capital Employeed (%), as of Mar 25, the value is 8.56. This value is below the healthy minimum of 10. It has decreased from 9.82 (Mar 24) to 8.56, marking a decrease of 1.26.
• For Return On Assets (%), as of Mar 25, the value is 3.71. This value is below the healthy minimum of 5. It has decreased from 4.83 (Mar 24) to 3.71, marking a decrease of 1.12.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.06, marking an increase of 0.05.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.11. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.11, marking an increase of 0.06.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.87. It has decreased from 1.02 (Mar 24) to 0.87, marking a decrease of 0.15.
• For Current Ratio (X), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 1.5. It has decreased from 1.41 (Mar 24) to 1.23, marking a decrease of 0.18.
• For Quick Ratio (X), as of Mar 25, the value is 0.44. This value is below the healthy minimum of 1. It has decreased from 0.53 (Mar 24) to 0.44, marking a decrease of 0.09.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.77. This value is below the healthy minimum of 4. It has decreased from 3.14 (Mar 24) to 2.77, marking a decrease of 0.37.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 19.39 (Mar 24) to 0.00, marking a decrease of 19.39.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 11.82 (Mar 24) to 0.00, marking a decrease of 11.82.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 80.61 (Mar 24) to 0.00, marking a decrease of 80.61.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 88.18 (Mar 24) to 0.00, marking a decrease of 88.18.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 12.49. This value is within the healthy range. It has decreased from 16.44 (Mar 24) to 12.49, marking a decrease of 3.95.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.23. This value is within the healthy range. It has decreased from 8.61 (Mar 24) to 6.23, marking a decrease of 2.38.
• For Enterprise Value (Cr.), as of Mar 25, the value is 32,023.54. It has increased from 26,264.11 (Mar 24) to 32,023.54, marking an increase of 5,759.43.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.86. This value is within the healthy range. It has increased from 1.57 (Mar 24) to 1.86, marking an increase of 0.29.
• For EV / EBITDA (X), as of Mar 25, the value is 16.76. This value exceeds the healthy maximum of 15. It has increased from 13.77 (Mar 24) to 16.76, marking an increase of 2.99.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.78, marking an increase of 0.24.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 80.60 (Mar 24) to 0.00, marking a decrease of 80.60.
• For Price / BV (X), as of Mar 25, the value is 2.20. This value is within the healthy range. It has increased from 2.01 (Mar 24) to 2.20, marking an increase of 0.19.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.78. This value is within the healthy range. It has increased from 1.54 (Mar 24) to 1.78, marking an increase of 0.24.
• For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness